Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

By M. Charlton, J. Burns, R. Pedersen, K. Watt, J. Heimbach, R. Dierkhising. Gastroenterology, 2011

1,087 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/e3170547e4b09238149a2f6141ee3fd15ce500c3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. G. Targher
4. K. Cusi
5. Gerald I. Shulman
6. A. Sanyal
7. S. Friedman
8. Q. Anstee

In Hepatology

1. Z. Younossi
2. S. Friedman
3. M. Rinella
4. J. Clark
5. R. Loomba
6. K. Cusi
7. Gerald I. Shulman
8. G. Targher

In Surgery

1. S. Friedman
2. Christopher D. Byrne
3. Gerald I. Shulman
4. Bart Staels
5. G. Targher

Citations in the corpus

• Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. (2015, background): “>30 kg/m(2)) patients with cryptogenic cirrhosis (CC).(9,10) Our”
• Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation (2014, background): “7% in 2009.(152) NASH is now the third most common indication for LT and is on pace to become the most frequent.”
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes (2016, background): “In this context, NASH has been recognized as one of the leading causes of cirrhosis in adults in the United States,((1-11)) and NASHrelated cirrhosis is currently the second indication for liver transplants in the United States.((8,9)) Clinically, NAFLD patients tend to be obese, with insulin resist”
• Increased de novo Lipogenesis is a Distinct Characteristic of Individuals with Nonalcoholic Fatty Liver Disease (2013, neutral): “118 T(NAFLD) is increasing, and this condition will become the most common liver disease in the United States over the next 10 years.(2,3) A comprehensive understanding”
• Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. (2013, result): “However, our data indicate that NAFLD is a more common condition, and its potential role as an underlying factor in these increases deserves attention, especially given recent supporting research (34, 35).”
• NAFLD: a multisystem disease. (2015, background): “In 2009, patients with NASH accounted for 10% of patients undergoing liver transplantation in the United States; NASH is the third most common indication for liver transplantation in the United States, and considering the spectrum of disease encapsulated within NAFLD, NAFLD is on a trajectory to bec”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “There is growing evidence that patients with histological NASH, especially those with some degree of fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality.((1,18,19,41-52)) These studies have also shown the following:”